Lipoprotein Electrophoresis
Elevated levels of lipids in the blood are associated with increased risk of atherosclerosis and its major complications, myocardial infarction and stroke. Lipids circulate in the blood as lipoproteins, or lipids bound to protein molecules.
Different types of lipoproteins can be defined based on the percentage of cholesterol, free fatty acids, glycerides, cholesterol esters, and protein within the molecule. Chylomicrons and very-low-density lipoproteins (VLDL) have relatively higher percentages of triglycerides, and high-density lipoproteins have higher percentages of protein; low-density lipoproteins (LDL) and intermediate-density lipoproteins (IDL) have levels of fat and protein between these two extremes.
LDL molecules transport fat and cholesterol from the liver to other organs and tissues, and high LDL levels are associated with increased cardiovascular risk. HDL molecules transport fat and cholesterol in the reverse, from the body to the liver for metabolism; high HDL levels are protective against cardiovascular disease.
Electrophoresis is one method to separate lipoproteins into their various fractions. The Fredrickson classification identifies six types of dyslipidemia-based abnormal elevations of the lipoprotein fractions as follows:
Type I: Elevated chylomicrons Type IIa: Elevated LDL Type IIb: Elevated LDL/VLDL Type III: Elevated LDL Type IV: Elevated VLDL Type V: Elevated chylomicron and VLDL
Types IIb and IV are the most common dyslipidemias in the United States, accounting for 85% of all familial cases. Type IIb dyslipidemia can be inherited (familial combined hyperlipoproteinemia or cholesteryl ester storage disease) or secondary, when it usually occurs in the context of metabolic syndrome. Type IV dyslipidemia (familial hypertriglyceridemia) is an autosomal dominant inherited disorder.
Treatment protocols are different for the various types of dyslipidemia; thus, the determination of lipoprotein levels is useful for accurate diagnosis and provision of appropriate therapy.
- Evaluating the risk for cardiovascular disease
- Monitoring therapy for cardiovascular disease or high cholesterol levels
- Diagnosing familial and secondary dyslipidemia syndromes
Chylomicrons increased in:
- Buerger-Gruetz syndrome or familial hyperchylomicronemia
- Familial apoprotein CII deficiency
LDL increased in:
- Familial hypercholesterolemia
- Familial combined hyperlipidemia
- Secondary hyperlipidemia
VLDL increased in:
- Familial combined hyperlipidemia
- Familial hypertriglyceridemia
IDL increased in:
- Familial dysbetalipoproteinemia
| Chylomicrons | Normal Range |
| Adults and Children | Undetectable |
| LDL – Adults | Reference Range |
| Desirable | <100 mg/dL |
| Above Desirable | 100-129 mg/dL |
| Borderline high | 130-159 mg/dL |
| High | 160-189 mg/dL |
| Very high | > or =190 mg/dL |
| LDL – Children (<17 years) | Reference Range |
| Acceptable | <110 mg/dL |
| Borderline high | 110-129 mg/dL |
| High | > or =130 mg/dL |
| VLDL | Normal Range |
| Adults and Children | <30 mg/dL |
Serum (SST tube).
Note: patients should be fasting for at least 12 hours.
Stability
- Ambient: 1-3 days
- Refrigerated: 7 days
- J Clin Lipidol. 2014;8(5):473-488 [PMID: 25234560]
- Pediatrics. 2011 Dec;128 Suppl 5:S213-S256 [PMID: 22084329]
- JAMA. 2001;285:2486-97 [PMID: 11368702]
- Circulation. 1965;31:321-7 [PMID: 14262568]
- J Clin Endocrinol Metab. 2003;88:2445-61 [PMID: 12788840]